Literature DB >> 1553346

Factors affecting the release rate of terbutaline from liposome formulations after intratracheal instillation in the guinea pig.

R M Fielding1, R M Abra.   

Abstract

Maximum duration of bronchodilator efficacy in inhaled liposome-based formulations depends on optimizing the in vivo release rate of the encapsulated bronchodilator. We investigated the effect of several formulation variables on the pulmonary residence time of 3H-terbutaline sulfate liposomes administered intratracheally in guinea pigs, using an improved method enabling the measurement of pulmonary drug absorption for extended periods of time in conscious animals. Half-lives of liposome-encapsulated 3H-terbutaline disappearance from the lungs and airways after instillation ranged from 1.4 to 18 hr and were markedly affected by liposome size, cholesterol content, and phospholipid composition. This study demonstrates that liposomes can significantly prolong the residence time of bronchodilators in the lungs and that precise control over the pulmonary residence time of encapsulated bronchodilators can be achieved by controlling formulation variables.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1553346     DOI: 10.1023/a:1018989423909

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  8 in total

1.  Pulmonary distribution of particles given by intratracheal instillation or by aerosol inhalation.

Authors:  J D Brain; D E Knudson; S P Sorokin; M A Davis
Journal:  Environ Res       Date:  1976-02       Impact factor: 6.498

2.  Absorption of drugs from the rat lung.

Authors:  S J Enna; L S Schanker
Journal:  Am J Physiol       Date:  1972-11

Review 3.  Fate and behavior of liposomes in vivo: a review of controlling factors.

Authors:  J H Senior
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  1987       Impact factor: 4.889

4.  Effects of dose and vesicle size on the pharmacokinetics of liposomes.

Authors:  Y Sato; H Kiwada; Y Kato
Journal:  Chem Pharm Bull (Tokyo)       Date:  1986-10       Impact factor: 1.645

5.  Absorption of aerosolized drugs from the rat lung.

Authors:  R A Brown; L S Schanker
Journal:  Drug Metab Dispos       Date:  1983 Jul-Aug       Impact factor: 3.922

6.  Uptake and biotransformation of ibuterol and terbutaline in isolated perfused rat and guinea pig lungs.

Authors:  A Ryrfeldt; E Nilsson
Journal:  Biochem Pharmacol       Date:  1978-02-01       Impact factor: 5.858

7.  Species comparison of drug absorption from the lung after aerosol inhalation or intratracheal injection.

Authors:  L S Schanker; E W Mitchell; R A Brown
Journal:  Drug Metab Dispos       Date:  1986 Jan-Feb       Impact factor: 3.922

8.  The physiological disposition of ibuterol, terbutaline and isoproterenol after endotracheal instillation to rats.

Authors:  A Ryrfeldt; N O Bodin
Journal:  Xenobiotica       Date:  1975-09       Impact factor: 1.908

  8 in total
  6 in total

Review 1.  Carrier-based strategies for targeting protein and peptide drugs to the lungs.

Authors:  Sally-Ann Cryan
Journal:  AAPS J       Date:  2005-03-24       Impact factor: 4.009

2.  Effect of dose and release rate on pulmonary targeting of liposomal triamcinolone acetonide phosphate.

Authors:  S Suarez; R J Gonzalez-Rothi; H Schreier; G Hochhaus
Journal:  Pharm Res       Date:  1998-03       Impact factor: 4.200

3.  Pulmonary delivery of free and liposomal insulin.

Authors:  F Y Liu; Z Shao; D O Kildsig; A K Mitra
Journal:  Pharm Res       Date:  1993-02       Impact factor: 4.200

4.  Pulmonary targeting of liposomal triamcinolone acetonide phosphate.

Authors:  R J Gonzalez-Rothi; S Suarez; G Hochhaus; H Schreier; A Lukyanov; H Derendorf; T D Costa
Journal:  Pharm Res       Date:  1996-11       Impact factor: 4.200

5.  Chapter 9 - Nanoliposomal dry powder formulations.

Authors:  Gaurang Patel; Mahavir Chougule; Mandip Singh; Ambikanandan Misra
Journal:  Methods Enzymol       Date:  2009       Impact factor: 1.600

Review 6.  Inhaled chemotherapy in lung cancer: future concept of nanomedicine.

Authors:  Paul Zarogoulidis; Ekaterini Chatzaki; Konstantinos Porpodis; Kalliopi Domvri; Wolfgang Hohenforst-Schmidt; Eugene P Goldberg; Nikos Karamanos; Konstantinos Zarogoulidis
Journal:  Int J Nanomedicine       Date:  2012-03-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.